⌕
Corvus Pharmaceuticals · CRVS · Nasdaq
Tenet 52 · Mixed
Compare
$10.17−4.06%At closeTenet 52 · Mixed
$10.17−0.43 (−4.06%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Corvus Pharmaceuticals (CRVS) Institutional Ownership

13F filers reported holding 83.9% of Corvus Pharmaceuticals (CRVS) shares as of Sep 30, 2026, across 175 filers.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice
Held by 13F filers
83.9%
Sep 30, 2026
13F filers
175
quarter ended Sep 30, 2026
13F value
$815.0M
70.7M shares
Quarter's fund flow
Mild accumulation
25 new · 18 closed

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

13F fund flowQuarter ended Sep 30, 2026: more funds added or entered than trimmed or exited, mild accumulation (25 new · 55 increased · 61 reduced · 18 closed · 16 unchanged or with no prior quarter on file). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
Basis: shares reported by 175 13F filers for Sep 30, 2026, over shares outstanding implied from the current quote, measured 49 days apart. It measures the ownership we have filings for, not total institutional ownership, and it moves with the share count between filings.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Nov 13, 2026Arcara JeffreyChief Business OfficerAcquired · Open-market buy503$10.37↗
Nov 13, 2026Arcara JeffreyChief Business OfficerAcquired · Open-market buy500$10.71↗
Nov 12, 2026Arcara JeffreyChief Business OfficerAcquired · Open-market buy497$11.12↗
Nov 11, 2026Arcara JeffreyChief Business OfficerAcquired · Open-market buy3,000$11.46↗
Jun 11, 2026Moore David ScottdirectorAcquired · Open-market buy21,700$11.53↗
Jun 11, 2026Moore David ScottdirectorAcquired · Grant / award15,000Stock Option (Right to Buy)—↗
Jun 11, 2026CLARK IAN TdirectorAcquired · Grant / award15,000Stock Option (Right to Buy)—↗
Jun 11, 2026Grais Linda SdirectorAcquired · Grant / award15,000Stock Option (Right to Buy)—↗
Jun 11, 2026Thompson Peter A.directorAcquired · Grant / award15,000Stock Option (Right to Buy)—↗
Jun 11, 2026van den Broek RicharddirectorAcquired · Grant / award15,000Stock Option (Right to Buy)—↗
May 18, 2026MILLER RICHARD A MDPresident and CEOAcquired · Open-market buy5,000$12.05↗
May 18, 2026MILLER RICHARD A MDPresident and CEOAcquired · Open-market buy1,932$12.01↗
Apr 23, 2026Chan Andrew C.directorAcquired · Grant / award30,000Stock Option (Right to Buy)—↗
Jan 28, 2026Thompson Peter A.directorAcquired · Option exercise30,000$15.00↗
Jan 28, 2026Thompson Peter A.directorAcquired · Option exercise15,000$9.70↗
Jan 28, 2026Thompson Peter A.directorAcquired · Option exercise15,000$12.50↗
Jan 28, 2026Thompson Peter A.directorAcquired · Option exercise15,000$3.61↗
Jan 28, 2026Thompson Peter A.directorAcquired · Option exercise15,000$2.00↗
Jan 28, 2026Thompson Peter A.directorAcquired · Option exercise15,000$3.27↗
Jan 28, 2026Thompson Peter A.directorAcquired · Option exercise15,000$2.74↗

* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How much of Corvus Pharmaceuticals do institutions hold?

13F filers reported holding 83.9% of Corvus Pharmaceuticals' shares as of Sep 30, 2026, across 175 filers.

How many 13F filers hold Corvus Pharmaceuticals?

Corvus Pharmaceuticals was held by 175 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.